Pipeline

HORAMA has established a pipeline of gene therapy candidates to treat rare ophthalmic diseases, including retinopathies and maculopathies.
Pipeline

Partnering Opportunities

At Horama, we are always interested in engaging with potential partners to synergize product development. We are actively seeking partnerships to advance our programs in gene therapy to treat genetic mutations in RLBP1 and RPE65, both of which contribute to inherited retinitis pigmentosa.